Concerta Fact Sheet

Medication Name (brand):

Concerta

Medication Name (clinical):

methylphenidate extended release

Manufacturer:

McNeil, marketing exclusivity expires 2008

Indications:

Attention Deficit Hyperactivity Disorder in children and adolescents

Mechanism:

Blocks reuptake of norepinephrine and dopamine

Dosing:

Supplied as 18 mg yellow, 27 mg gray, 36 mg white, and 54 mg brownish-red tablets (not breakable due to extended release vehicle).
Start at 18 mg QAM, and increase gradually to achieve a response.
Maximum recommended dose 54 mg in children, 72 mg in adults.

Side Effects:

Most common are decreased appetite, weight loss, tics, and nausea.
All stimulants are required to carry a warning about the possibility of sudden death, primarily in children with pre-existing cardiac abnormalities.
Risk of stimulant abuse and diversion (Schedule II controlled substance).
Growth suppression, usually mild, is possible with all stimulants.
Pregnancy Category C.

Drug-drug Interactions:

Avoid in combination with MAOIs.

Pharmokinetics:

Metabolized by the liver.
Lasts 8-12 hours.
Half-life is 3-4 hours.

Return to

ADHD

issue area